Zobrazeno 1 - 10
of 10 839
pro vyhledávání: '"debulking"'
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5630-5642 (2024)
Background: Extensive surgery on advanced-stage epithelial ovarian cancer is associated with increased postoperative morbidity, which may cause a delay in or omission of chemotherapy. We examined postoperative complications and their effects on adjuv
Externí odkaz:
https://doaj.org/article/4ea564298dcf4c51b33e788314e59995
Autor:
Kazuki Takasaki, Takayuki Ichinose, Haruka Nishida, Yuko Miyagawa, Kei Hashimoto, Saya Watanabe, Yuko Takahashi, Mana Hirano, Haruko Hiraike, Yuko Sasajima, Kazunori Nagasaka
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-9 (2024)
Abstract Background Interval debulking surgery (IDS) following neoadjuvant chemotherapy is a treatment option for advanced ovarian cancer. Optimal surgery is required for better survival; however, while peritoneal washing cytology (PWC) has been iden
Externí odkaz:
https://doaj.org/article/f301ecf220ec427199c8bbe791876ede
Publikováno v:
The Cardiothoracic Surgeon, Vol 32, Iss 1, Pp 1-21 (2024)
Abstract Background Infective endocarditis is an infection of microbial origin affecting the endocardial layer of the heart, mostly impacting the heart valves. Right-sided infective endocarditis mainly affects the tricuspid valve. In some cases where
Externí odkaz:
https://doaj.org/article/1a8408ecfd834cddabd2d49bb28dbdfe
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background This systematic review and meta-analysis aimed to consolidate the existing evidence regarding the comparison between en-bloc resection surgery and debulking surgery for spinal tumors, including both primary and metastatic tumors.
Externí odkaz:
https://doaj.org/article/152e82c892a844bc972bb68af4782ec6
Publikováno v:
Asian Journal of Surgery, Vol 47, Iss 8, Pp 3442-3447 (2024)
Background: Given the limited studies addressing the issue about the effect of different surgical modalities for metastatic spinal cord compression (MSCC) as the first malignancy manifestation, we conducted a retrospective case-control study to evalu
Externí odkaz:
https://doaj.org/article/2ae053a32ba44e0d8ad6d604bec0a45a
Publikováno v:
Опухоли женской репродуктивной системы, Vol 20, Iss 1, Pp 124-130 (2024)
Standard treatment for advanced ovarian cancer (OC) consists of a combination of chemotherapy and cytoreductive surgery, but practice varies depending on the order of these 2 procedures: neoadjuvant chemotherapy followed by interval debulking surgery
Externí odkaz:
https://doaj.org/article/be10619ed4c645b1a3f39d84127dae35
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 761-769 (2024)
Yuexi Liu,* Qiuying Gu,* Yao Xiao, Xing Wei, Jinlong Wang, Xiaolan Huang, Hua Linghu Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China*These authors contribute
Externí odkaz:
https://doaj.org/article/2145c43fcb5c4b42911b81686074d7b6
Publikováno v:
Insights into Imaging, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Objectives To determine whether MRI can predict the necessity of rectosigmoid resection (RR) for optimal debulking surgery (ODS) in ovarian cancer (OC) patients and to compare the predictive accuracy of pre- and post-neoadjuvant chemotherapy
Externí odkaz:
https://doaj.org/article/8d29303463334505a706d1c96ea26a50
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background The modeled CA-125 elimination constant K (KELIM) is a potential marker of tumor chemosensitivity in ovarian cancer patients treated with neoadjuvant chemotherapy (NACT) before interval surgery. The objective of this study was to
Externí odkaz:
https://doaj.org/article/5ac3871dbf65485db7dc06c931b23d0a
Autor:
Jimmy Belotte, Brunella Felicetti, Amanda J. Baines, Ahmed YoussefAgha, Luis Rojas-Espaillat, Ana Godoy Ortiz, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, has been shown to extend progression-free survival in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based ch
Externí odkaz:
https://doaj.org/article/6a0a2a80b0c94cb1a14431371e664115